共 50 条
- [21] Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI plus ): Interim analysis of an open-label randomised controlled trialPLOS MEDICINE, 2021, 18 (01)Jackson, Graham H.Pawlyn, CharlotteCairns, David A.de Tute, Ruth M.Hockaday, AnnaCollett, CorinneJones, John R.Kishore, BhuvanGarg, MamtaWilliams, Cathy D.Karunanithi, KamarajLindsay, JindriskaRocci, AlbertoSnowden, John A.Jenner, Matthew W.Cook, GordonRussell, Nigel H.Drayson, Mark T.Gregory, Walter M.Kaiser, Martin F.Owen, Roger G.Davies, Faith E.Morgan, Gareth J.
- [22] A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma PatientsBLOOD, 2020, 136Silvennoinen, Raija HelenaWaage, AndersPeceliunas, ValdasSchjesvold, FredrikMdphdAnttila, PekkaSaily, MarjaanaPutkonen, MerviCarlson, KristinaHaukaas, EinarSankelo, MarjaPartanen, AnuSzatkowski, Damian L.Hansson, MarkusMarttila, AnuAhlberg, LuciaAxelsson, PerLauri, BirgittaMikkola, Maija HelenaKarlsson, ConnyAbelsson, JohannaAhlstrand, ErikSikio, AnuKlimkowska, MonikaMatuzeviciene, RedaFenstad, Mona HoysaeterIlveskero, SorellaNahi, Hareth
- [23] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 studyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Knop, StefanStuebig, ThomasKull, MiriamGreil, RichardSteiner, NormannBassermann, FlorianNogai, Axelvon Lilienfeld-Toal, MarieJanjetovic, SnjezanaTrautmann-Grill, KarolinBittrich, MaxEngelhardt, Monika MarthaHoferer, AnetteTheurich, SebastianBinder, MaschaZojer, NiklasDuerk, Heinz A.Brueggemann, MonikaHeld, SwantjeEinsele, Hermann
- [24] A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple MyelomaBLOOD, 2014, 124 (21)Bensinger, William I.Vescio, RobertGasparetto, CristinaCamacho, Elber S.Nath, RajneeshGomes, Christina L.Smith, David D.Shah, Jatin J.Durie, Brian G. M.
- [25] A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple MyelomaBLOOD, 2015, 126 (23)Silvennoinen, RaijaAnttila, PekkaSaily, MarjaanaLundan, TuijaHeiskanen, JouniSiitonen, TimoKakko, SakariPutkonen, MerviOllikainen, HannaTerava, VenlaPartanen, AnuLaunonen, KirsiRasanen, AnuSiklo, AnuSuominen, MerjaBazia, PiotrKananen, KristiinaSelander, TuomasKuittinen, TaruPorkka, KimmoRemes, KariJantunen, Esa
- [26] Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)BLOOD, 2017, 130Ishida, TadaoOzaki, ShujiKimura, HideoKubo, KoumeiSunami, KazutakaTakezako, NaokiFujita, HiroyukiHayashi, ToshiakiKiguchi, ToruKobayashi, TakeshiYamamoto, SatoshiTakamatsu, HiroyukiKosugi, HiroshiOhta, KensukeSakai, RikaHanda, HiroshiHisatomi, TakashiAbe, YuSasaki, KoOmoto, EijiroMurakami, HirokazuShimizu, Kazuyuki
- [27] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for transplant-ineligible multiple myeloma: update of a multi-center prospective study in ChinaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S104 - S104Zhuang, ZheTian, YingYu, HongShi, LeiTian, Wei-weiLiu, QinhuaZou, DongmeiDong, FeiFeng, RuMa, YanpingLiu, ShuangjiaoLiu, HuiJing, HongmeiSun, WanlingMa, Liang-MingBao, LiFu, RongWu, YinChen, WenmingZhuang, Junling
- [28] Efficacy of Isatuximab-Based Regimens Compared to Standard of Care in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Phase III Clinical TrialsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S557 - S558Anwar, JunaidAnjum, ZauraizZarrar, RazaMandal, ShobhaAhmed, Mirza FawadArslan, Hafiz MuhammadTariq, MahrukhNazar, TazeenAziz, BilalAhmed, ZahoorKhan, MuzamilAnwer, Faiz
- [29] An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Laubach, JacobNooka, Ajay K.Cole, CraigO'Donnell, ElizabethVij, RaviUsmani, Saad ZafarOrloff, Gregory JoshuaRichter, Joshua RyanRedd, RobertDiPietro, HeidiCummings, KristenHansen, JoshuaHenrick, Patrick M.Bassett, PaulSchachter, HaleyRichardson, Paul G.Lonial, Sagar
- [30] An Ongoing Phase 2, Multi-Center, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease PatientsHEPATOLOGY, 2016, 64 : 281A - 282ASchilsky, Michael L.Askari, Frederick K.Ferenci, PeterCzlonkowska, AnnaNicholl, David J.Bronstein, JeffreyBega, DannyWeiss, Karl Heinz